Editas Medicine Halts ATM Stock Sales After Raising $43.9M

Editas Medicine, Inc. has suspended and terminated the prospectus supplement for its "at-the-market" (ATM) offering program with TD Cowen, effective May 26, 2026. The company will not sell any more common stock under this program until a new prospectus or supplement is filed and declared effective by the SEC. Prior to this suspension, Editas Medicine had issued and sold 14,327,365 shares of common stock, generating aggregate gross proceeds of $43.9 million. The underlying Sales Agreement with TD Cowen remains in full force and effect.